Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy rating and $46.00 price target

Analyst Ratings For Adaptive Biotechnologies Corp (NASDAQ:ADPT)

Story continues below

Today, BTIG Research initiated coverage on Adaptive Biotechnologies Corp (NASDAQ:ADPT) with a Buy with a price target of $46.00.

There are 6 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Adaptive Biotechnologies Corp (NASDAQ:ADPT) is Buy with a consensus target price of $43.00 per share, a potential 9.50% upside.

Some recent analyst ratings include

  • 7/23/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy rating and $46.00 price target
  • 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Outperform ➝ Outperform rating
  • 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Outperform ➝ Outperform rating
  • 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy ➝ Buy rating and $47.00 price target
  • 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy ➝ Buy rating and $45.00 price target
  • 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Overweight rating and $45.00 price target
  • 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Neutral ➝ Neutral rating and $32.00 price target

    Recent Trading Activity for Adaptive Biotechnologies Corp (NASDAQ:ADPT)
    Shares of Adaptive Biotechnologies Corp closed the previous trading session at 39.27 up +0.74 1.92% with shares trading hands.

    An ad to help with our costs